Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 1, 2016, Pages 8-14

  Thijssen, Annemieke Y ^a   Clemens, Cees H M ^b   Vankerckhoven, Vanessa ^c   Goossens, Herman ^c   Jonkers, Daisy M A E ^a   Masclee, Ad A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Internal Medicine   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Irritable bowel syndrome; Placebo effect; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; ASSESSMENT OF HUMANS; BACTERIAL STRAIN; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTENTION TO TREAT ANALYSIS; IRRITABLE COLON; LACTOBACILLUS CASEI; MALE; MEAN SYMPTOM SCORE; MEDICATION COMPLIANCE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS CASEI; MALE; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84983126765     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000484     Document Type: Article

References (54)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130:1480-1491.
2. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17:643-650.
3. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41:2248-2253.
4. Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134 (Pt 2):860-868.
5. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95:2698-2709.
6. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl 2):1-9.
7. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5:185-194.
8. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43:213-222.
9. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, et al. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol 2008; 42 (Suppl 3 Pt 2):S214-S217.
10. Shida K, Nanno M. Probiotics and immunology: separating the wheat from the chaff. Trends Immunol 2008; 29:565-573.
11. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt L, Quigley E. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-332.
12. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14:581-587.
13. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104:1033-1049; quiz 1050.
14. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24:925-931.
15. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32:294-301.
16. Simren M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effect of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome (IBS)-a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2009; 29:508-518.
17. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013; 13:45.
18. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 2010; 10:16.
19. Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012; 18:112-119.
20. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, et al. Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62:159-176.
21. Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998; 52:899-907.
22. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17:655-659.
23. Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol 2008; 14:5020-5024.
24. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal microflora: probiotics and autoimmunity. J Nutr 2007; 137 (Suppl 2): 798S-802S.
25. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, Morotomi M. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Int J Food Microbiol 1999; 48:51-57.
26. van der Veek PP, van Rood YR, Masclee AA. Clinical trial: short-and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:943-952.
27. van der Zee KI, Sanderman R. Assessment of general health status with the RAND-36; guidebook. Northern Centre for Health Questions Groningen University: Groningen 1993.
28. Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes 2007; 5:54.
29. Gonsalkorale WM, Toner BB, Whorwell PJ. Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004; 56:271-278.
30. Toner BB, Stuckless N, Ali A, Downie F, Emmott S, Akman D. The development of a cognitive scale for functional bowel disorders. Psychosom Med 1998; 60:492-497.
31. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130:1538-1551.
32. Goossens D, Jonkers D, Russel M, Stobberingh E, Van Den Bogaard A, StockbrUgger R. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther 2003; 18:495-505.
33. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007; 5:534-540.
34. Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013; 4:201-211.
35. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009; 29:97-103.
36. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, Kyronpalo S, Rasmussen M, Jarvenpaa S, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27:48-57.
37. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a doubleblind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-1132.
38. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702.
39. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551.
40. Takeda K, Okumura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human NK-cell activity. J Nutr 2007; 137 (Suppl 2):791S-793SS.
41. Koning CJ, Jonkers DMAE, Stobberingh EE, Out TA, Stockbrugger RW. Effect of a multispecies probiotic on components of the mucosal and systemic immune system in healty volunteers treated with amoxycillin. Gut Pathogens 2005; 54 (Suppl VIII):A260.
42. Klosterhalfen S, Enck P. Psychobiology of the placebo response. Auton Neurosci 2006; 125:94-99.
43. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002; 123:1686-1701.
44. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13:1149-1159.
45. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al. The placebo effect in irritable bowel syndrome trials: a metaanalysis. Neurogastroenterol Motil 2005; 17:332-340.
46. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336:999-1003.
47. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, Nam BH, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007; 19:630-637.
48. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:237-247.
49. Flaten MA, Aslaksen PM, Finset A, Simonsen T, Johansen O. Cognitive and emotional factors in placebo analgesia. J Psychosom Res 2006; 61:81-89.
50. Kelley JM, Lembo AJ, Ablon JS, Villanueva JJ, Conboy LA, Levy R, et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 2009; 71:789-797.
51. MacDonald AJ, Peden NR, Hayton R, Mallinson CN, Roberts D, Wormsley KG. Symptom relief and the placebo effect in the trial of an anti-peptic drug. Gut 1981; 22:323-326.
52. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5:e15591.
53. Drossmann DA. The functional gastrointestinal disorders and the ROME III process. Gastroenterology 2006; 130:1377-1390.
54. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107 (5A):91S-97S.